

SAFETY DATA SHEET

Spectrazol Milking Cow®

Section 1: Identification of the Substance and Supplier

Product name	Spectrazol Milking Cow Liquid containing 9.2 – 9.5% cefuroxime sodium
Recommended use	For treatment of clinical mastitis in lactating cows
Company details	MSD Animal Health, 33 Whakatiki Street, Upper Hutt Phone: 0800 800 543 Fax: 0800 808 100 Website: www.msd-animal-health.co.nz Hours: 8 am – 5 pm, Mon – Fri
Emergency telephone	0800 764 766 (0800 POISON) 24 hours human health 0800 243 622 (0800 CHEMCALL) 24 hours
Date of preparation	September 2011

Section 2: Hazards Identification

Hazard classifications	6.3B, 6.5B
Priority identifiers	WARNING
Secondary identifier	6.3B May cause mild skin irritation 6.5B May cause an allergic skin reaction
Risk & Safety Phrases	R43 May cause sensitisation by skin contact

Section 3: Composition/Information on Ingredients

Chemical name	CAS number	Concentration
Cefuroxime sodium	56238-63-2	9.22%

Section 4: First Aid Measures

Necessary first aid measures

SKIN CONTACT In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.

EYE CONTACT In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.

INGESTION Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Centre. If symptoms persist, consult a doctor.

INHALATION Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a doctor.

SAFETY DATA SHEET

Spectrazol Milking Cow[®]

Page 2 of 4

Required instructions	For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.
Notes for medical personnel	Cefuroxime sodium is a cephalosporin. Cephalosporins may cause hypersensitivity reactions including anaphylaxis, skin rashes, fever, or skin rashes in susceptible individuals. Contact dermatitis developed in nurses exposed to a similar cephalosporin, and another cephalosporin may have cause a photosensitization reaction. Ingestion of cephalosporins may produce gastrointestinal effects including nausea, vomiting, or diarrhoea. Other effects that may occur include headache, confusion, restlessness, agitation, ringing in the ears, muscle incoordination, double vision, decreased white blood cells, platelets, and red blood cell counts, or kidney effects. Cefuroxime sodium readily crosses the placenta and into human breast milk in small amounts.
Workplace facilities	Emergency showers and eyewashes may be warranted depending on quantity and type of use.

Section 5: Fire Fighting Measures

Type of hazard	Not classified as flammable
Fire hazard properties	Not applicable
Regulatory requirements	Not applicable
Extinguishing media and methods	Carbon dioxide (CO ₂), extinguishing powder or water spray.
Hazchem code	Not applicable
Recommended protective clothing	Wear full protective clothing and self-contained breathing apparatus (SCBA).

Section 6: Accidental Release Measures

Emergency procedures	Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Adsorb spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal.
-----------------------------	---

Section 7: Handling and Storage

Precautions for safe handling	Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.
Regulatory requirements	Emergency Plan required where quantities greater than 1000L are present.
Handling practices	Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.
Approved handlers	Store in original container in a cool, dry, ventilated place away from direct heat or direct sunlight. Keep container sealed when not in use. Keep out of reach of children.
Conditions for safe storage	Store in original container in a cool, dry, ventilated place. Keep container sealed when not in use. Keep out of reach of children.
Store site requirements	Store below 25°C. Do not refrigerate.
Packaging	PG III

SAFETY DATA SHEET

Spectrazol Milking Cow®

Section 8: Exposure Control/Personal Protection

Workplace exposure standards	No WES have been set for this substance
Application in the workplace	Ensure adequate ventilation. Keep container sealed when not in use.
Exposure standards outside the workplace	No TEL is set for this substance at this time EEL – not applicable
Personal protection	Wear chemical resistant gloves, facemask or goggles.

Section 9: Physical and Chemical Properties

Appearance	A smooth white to cream suspension.
Boiling Point	Not determined
Melting/Softening point	Not applicable
Vapour Pressure	Not determined
Specific Gravity	Not determined
Solubility (H ₂ O)	Insoluble
Percent Volatiles	Not determined

Section 10: Stability and Reactivity

Stability of the substance	Stable under normal conditions.
Conditions to avoid	Extremes of temperature. Direct light.
Material to avoid	Avoid food products
Hazardous decomposition products	No dangerous decomposition is expected if used according to manufacturer's specifications.

Section 11: Toxicological Information

Acute effects for individual ingredients only

ORAL	Cefuroxime sodium: Oral LD50 >10,000 mg/kg (rats), LD50 >10,000 mg/kg (mouse).
TEL	No TEL is set for this substance at this time.

Chronic effects for individual ingredients only

Cefuroxime sodium is not teratogenic in mice and rabbits. Rabbits given dosages of up to 150 mg/kg intravenously and subcutaneously on gestation days 6-18 had no adverse effects on the foetuses. Mice given dosages up to 3200 mg/kg/day showed no inhibition of fertility or foetal harm.

Cefuroxime sodium: Negative in mouse lymphoma assay and multiple bacterial mutation tests (Ames), Positive in in-vitro chromosome aberration, negative in in-vivo micronucleus test.

SAFETY DATA SHEET

Spectrazol Milking Cow[®]

Section 12: Environmental Information

Effects for active ingredient only

EEL	Not applicable
-----	----------------

Section 13: Disposal Considerations

Disposal information	Disposal Dispose of unused contents in a suitable landfill. Container Disposal Dispose of empty syringe by burying in a suitable landfill.
Reference	Current version of NZS 8409 Management of Agrichemicals

Section 14: Transport Information

Relevant information	Not classified as a dangerous good for transport
-----------------------------	--

Section 15: Regulatory Information

Regulatory status	ERMA Approval Code: HSR002277 For full listings of controls see www.epa.govt.nz ACVM Registration No: A5270 For conditions of registration see www.foodsafety.govt.nz RESTRICTED VETERINARY MEDICINE
HSNO and ACVM controls	Emergency Plan: 1000 Litres

Section 16: Other Information

Additional information	Spectrazol is a registered trademark.
-------------------------------	---------------------------------------

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Schering-Plough Animal Health Ltd extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).